Initial experience with a prototype dual-crystal (LSO/NaI) dual-head coincidence camera in oncology

Urvi Joshi, Otto S. Hoekstra, Ronald Boellaard, Emile F.I. Comans, Pieter G.H.M. Raijmakers, Rik J. Pijpers, Steven D. Miller, Gerrit J.J. Teule, Arthur Van Lingen

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)


The aim of this study was to evaluate the in vivo performance of a prototype dual-crystal [lutetium oxyorthosilicate (LSO)/sodium iodide (NaI)] dual-head coincidence camera (DHC) for PET and SPET (LSO-PS), in comparison to BGO-PET with fluorine-18 fluorodeoxyglucose (FDG) in oncology. This follows earlier reports that LSO-PS has noise-equivalent counting (NEC) rates comparable to partial ring BGO-PET, i.e. clearly higher than standard NaI DHCs. Twenty-four randomly selected oncological patients referred for whole-body FDG-PET underwent BGO-PET followed by LSO-PS. Four nuclear medicine physicians were randomised to read a single scan modality, in terms of lesion intensity, location and likelihood of malignancy. BGO-PET was considered the gold standard. Forty-eight lesions were classified as positive with BGO-PET, of which LSO-PS identified 73% (95% CI 60-86%). There was good observer agreement for both modalities in terms of intensity, location and interpretation. Lesions were missed by LSO-PS in 13 patients in the chest (n=6), neck (n=3) and abdomen (n=4). The diameter of these lesions was estimated to be 0.5-1 cm. Initial results justify further evaluation of LSO-PS in specific clinical situations, especially if a role as an instrument of triage for PET is foreseen.

Original languageEnglish
Pages (from-to)596-598
Number of pages3
JournalEuropean journal of nuclear medicine and molecular imaging
Issue number4
Publication statusPublished - 1 Jan 2004


  • Dual-head coincidence
  • Fluorodeoxyglucose
  • Lutetium oxyorthosilicate
  • Positron emission tomography

Cite this